Advertisement
Advertisement
U.S. markets close in 4 hours 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.28+0.71 (+5.23%)
As of 11:34AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.57
Open13.24
Bid14.35 x 1300
Ask14.43 x 1100
Day's Range12.88 - 14.75
52 Week Range6.25 - 17.80
Volume2,115,868
Avg. Volume878,214
Market Cap456.323M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACET

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adicet Bio, Inc.
    AAON: Raising target price to $83.00AAON INC has an Investment Rating of HOLD; a target price of $83.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy

    Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma (ORR=75%, CR=50%)No ADI-001-related serious adverse events, including GvHD, neurotoxicity or high-grade CRS have been reported to dateEvidence of in vivo expansion and circulating pharmacodynamic biomarkers consistent with ADI-001 activationFavorable safety and clinical activity reinforces the potential of Adicet’s first-in-class allogeneic,

  • GlobeNewswire

    Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma

    ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:3

  • GlobeNewswire

    Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

    MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors. "Dr. Kauffman’s appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-she

Advertisement
Advertisement